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Anaplastic large cell lymphoma repre-
sents a subset of neoplasms caused by
translocations that juxtapose the anaplas-
tic lymphoma kinase (ALK) to dimeriza-
tion partners. The constitutive activation
of ALK fusion proteins leads to cellular
transformation through a complex signal-
ing network. To elucidate the ALK path-
ways sustaining lymphomagenesis and
tumor maintenance, we analyzed the
tyrosine-kinase protein profiles of ALK-
positive cell lines using 2 complementary
proteomic-based approaches, taking ad-
vantage of a specific ALK RNA interfer-
ence (RNAi) or cell-permeable inhibitors.
A well-defined set of ALK-associated ty-
rosine phosphopeptides, including meta-
bolic enzymes, kinases, ribosomal and
cytoskeletal proteins, was identified. Vali-
dation studies confirmed that vasodilator-
stimulated phosphoprotein and 5-
aminoimidazole-4-carboxamide ribonucle-
otide formyltransferase/inosine mono-
phosphate cyclohydrolase (ATIC) associ-
ated with nucleophosmin (NPM)–ALK, and
their phosphorylation required ALK activ-
ity. ATIC phosphorylation was docu-
mented in cell lines and primary tumors
carrying ALK proteins and other tyrosine
kinases, including TPR-Met and wild type
c-Met. Functional analyses revealed that
ALK-mediated ATIC phosphorylation en-
hanced its enzymatic activity, dampening
the methotrexate-mediated transformy-
lase activity inhibition. These findings
demonstrate that proteomic approaches
in well-controlled experimental settings
allow the definition of informative pro-
teomic profiles and the discovery of novel
ALK downstream players that contribute
to the maintenance of the neoplastic phe-
notype. Prediction of tumor responses to
methotrexate may justify specific
molecular-based chemotherapy. (Blood.
2009;113:2776-2790)
Introduction
Cell transformation is the result of the sequential acquisition of
multiple genetic defects, which provide a growth and survival
advantage to the cancerous cells and the acquisition of metastatic
potential.1 The activation of oncogenes and the loss of tumor
suppressor genes are pivotal in cancer development, as they
deregulate multiple metabolic pathways and contribute to the
neoplastic phenotype. Better understanding of key metabolic
checkpoints in cancer cells would allow the design of novel
therapeutic strategies. Dividing cells heavily rely on de novo purine
synthesis, whereas normal cells prefer the salvage pathway.2
Glycinamide ribonucleotide formyltransferase and the bifunctional
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) formyl-
transferase/inosine monophosphate (IMP) cyclohydrolase (AICAR-
FT/IMP-CHase, named ATIC) have raised considerable attention
because of their role in cancer. Both enzymes are folate-dependent
and have become exquisite targets of chemotherapeutic
intervention.2-4
ATIC is a bifunctional enzyme that catalyzes the final 2 steps of
de novo purine biosynthesis pathway.3-5 The AICAR formyltrans-
ferase (AICAR-FT) domain (residues 199-592) catalyzes the
transfer of the one-carbon formyl group from the cofactor N10-
formyl-tetrahydrofolate (10-f-THF) to the substrate AICAR to
produce N-formyl-5-aminoimidazole-4-carboxamide ribonucle-
otide (F-AICAR) and tetrahydrofolate. The IMP cyclohydrolase
domain (IMP-Chase; residues 1-198) then enhances the intramolecu-
lar cyclization of N-formyl-AICAR to the final product of the
pathway, IMP.6
The ATIC gene is fused, as result of cryptic inversion [inv(2)
(9p23q35)], to the anaplastic lymphoma kinase (ALK) in a subset of
anaplastic large cell lymphoma (ALCL). ALCL, a distinct entity
among T-cell non-Hodgkin lymphoma (NHL), is a hematologic
disorder that accounts for approximately 30% of all pediatric
NHLs. Many ALCLs carry translocations that involve ALK and
variable partner genes (mainly nucleophosmin [NPM1]). In ATIC-
ALK, the N-terminus of ATIC fuses to the intracytoplasmic region
of ALK and encodes a novel oncogenic chimeric protein.7-9
ALK chimeras have constitutive tyrosine kinase activity with
oncogenic potential. In vitro and in vivo studies have demonstrated
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that ALK signaling induces cell transformation by modulating
many adaptor proteins involved in cell-cycle progression, survival,
cytoskeletal rearrangement, and cell migration.10 ALK signaling is
required and necessary to maintain the neoplastic phenotype
because the loss of ALK activity causes cell-cycle arrest and cell
death in vitro, and tumor regression in vivo.11,12 These findings
have fostered the discovery of ALK small-molecule inhibitors that
are now in early clinical trials or on the verge of entering the
clinical arena. The discovery that deregulated expression of ALK
can be seen in a subset of nonhematologic tumors, including
inflammatory myofibroblastic tumors, non–small cell lung cancer,
sarcoma, and neuroblastoma,12 has increased the interest on ALK,
as a promising target for specific therapies.
Because some signaling molecules essential for ALK-mediated
transformation10 display a key function in other ALK tumors,
several groups have undertaken high throughput (HTP) analyses,
including gene expression profiling assays13,14 and proteomic-
based approaches,15,16 to discover selective ALK targets. Liquid
chromatography–tandem mass spectrometry (LC-MS/MS) and
HTP proteomics focusing on tyrosine phosphopeptides provide a
fast and reliable method for large-scale analysis of cellular proteins
differentially expressed in normal and tumor samples, and it is a
powerful tool to identify selective signatures in kinase-driven
hematologic and nonhematologic malignancies.15,17-20
Here we used 2 complementary proteomic-based approaches to
dissect the ALK signaling. Taking advantage of shRNA and ALK
kinase inhibitors, we compared the differential ALK tyrosine-
phosphorylation profiling in different settings. We found that ALK
activity is associated with a defined set of phosphorylated proteins
regulating key cellular functions. Among novel ALK-associated
proteins, we have shown that vasodilator-stimulated phosphopro-
tein (VASP) and ATIC are directly phosphorylated by ALK. The
enzymatic activity of ATIC was enhanced after tyrosine phosphory-
lation via several oncogenes and phospho-ATIC was less efficiently
inhibited by the methotrexate. These findings provide novel
insights into ALK-mediated transformation and support the selec-
tion of tailored chemotherapeutic protocols.
Methods
Cell lines and reagents
Human ALCL cell lines TS (a subclone of Sup-M2), Sup-M2, JB-6,
SU-DHL1, and Karpas-299 were previously described.11-21 T-cell leukemic
cell lines CCRF-CEM and Jurkat were obtained from ATCC (Manassas,
VA); Mac-1 was kindly provided by Dr M. Kadin (Harvard University,
Boston, MA). Cell lines were grown at 37°C in 5% CO2 humidified air in
RPMI 1640 medium (Lonza Verviers SPRL, Verviers, Belgium).
HEK-293T and HEK-293T-Rex Tet-on NPM-ALK cells22 were grown
at 37°C in 5% CO2 humidified air in Iscove modified Dulbecco medium,
supplemented with 10% fetal calf serum. For antiphosphotyrosine immuno-
precipitation, HEK-293T-Rex Tet-on NPM-ALK cells were grown in
nonadherent conditions on poly (2-hydroxyethylmethacrylate; Sigma-
Aldrich, St Louis, MO)–coated plates, starved for 12 hours, and then
induced with 1 g/mL of tetracycline for 24 hours.
Self-inactivating retroviral particles for NPM-ALK and the kinase dead
mutant NPM-ALKK210R were produced as described previously.11 Aliquots
of virus, plus 8 g/mL of polybrene, were used to infect exponentially
growing cells (CCRF-CEM and Mac-1, 105/mL). Fresh medium was
supplemented 24 hours after infection. The infectivity was determined after
72 hours of infection by fluorescence-activated cell sorting analysis of
green fluorescent protein (GFP)–positive cells. GFP cells were sorted by
MoFlo High-Performance fluorescence-activated cell sorting (Dako North
America, Carpinteria, CA) and expanded.
For the kinase inhibition experiments, NPM-ALK–positive and
–negative cells were treated with 300 nM of CEP11988 or CEP1408323
for 6 hours.
Phosphopeptide immunoprecipitation and LC-MS/MS mass
spectrometry
Phosphopeptide immunoprecipitation from cell lines was performed as
described previously15 using the PhosphoScan Kit (P-Tyr-100) from Cell
Signaling Technology (Danvers, MA; Document S1, available on the Blood
website; see the Supplemental Materials link at the top of the online article).
All spectra and all sequence assignments obtained using Sequest
(Thermo Scientific, Waltham, MA) were then imported into a relational
database based on FileMaker Pro (FileMaker, Santa Clara, CA) and MySQL
(Sun Microsystems, Santa Clara, CA), as described.15 Comparison between large
datasets was performed using a custom-made Perl script (www.perl.com), to find
overlapping and/or recurrent sequences (see Document S1).
Anti-phosphotyrosine protein immunoprecipitation and
LC/MS-MS analysis
Anti-phosphotyrosine immunoprecipitation on HEK-293T-Rex Tet-on cells
(Invitrogen, Carlsbad, CA), transfected with a wild-type NPM-ALK or a
kinase-dead mutant control NPM-ALKK210R, and LC/MS-MS analyses
were performed as previously described.22 Protein identification via peptide
MS/MS spectra was achieved using the Mascot software (http://
matrixscience.com) for searching the National Center for Biotechnology
Information nonredundant human protein database (released April 29,
2003; containing 37 490 protein sequences).
Stable isotope labeling of amino acid in cell culture analysis of
shALK cells
Cells were grown in RPMI medium lacking arginine and lysine, supple-
mented with 10% dialyzed fetal bovine serum, penicillin/streptomycin, and
L-lysine/HCl and L-arginine/HCl (Sigma-Aldrich) for light cultures or
L-arginine/HCL (U-13C6, 98%) and L-lysine/2HCl (U-13C6, 98%; Cam-
bridge Isotope Laboratories, Andover, MA) for heavy cultures as de-
scribed.24,25 Cells were grown to a density of approximately 106 cells/mL
for a total of 108 cells per each cell culture type (2  108 cells total). After
lysis, heavy and light cultures were combined and carried through the
phosphopeptide immunoprecipitation protocol.
Protein immunoprecipitation and Western blotting
Immunoprecipitation and Western blot analysis were performed as de-
scribed previously26 (Document S1). The protein content of cell suspen-
sions was assessed with the Lowry kit from Bio-Rad (Hercules, CA).
The following primary antibodies were used: mouse anti-ALK (1:4000,
4C5B8) and anti-STAT3 (5G7) from Zymed Laboratories (South San
Francisco, CA); mouse anti–phospho-tyrosine (PY100; 1:2000), rabbit
anti–phospho STAT3 (Tyr 705, 1:1000), rabbit antiphospho-ERK1/2 (Thr202/
Thy204) (#9101 1:1000), rabbit anti–phospho-SHP2 (Tyr 542) (1:1000), rabbit
anti–phospho-SHC (Tyr 317) (1:1000), rabbit anti–phospho-ALK (Tyr 1604)
(1:1000), rabbit anti–SHC (1:1000), rabbit anti–p44/42 MAPK (1:1000), anti–
VASP (1:1000), and rabbit anti–SHP2 (1:1000) from Cell Signaling Technology;
mouse anti-actin (1:2000) from Millipore (Billerica, MA); mouse anti-ATIC
(1:1000) from Abcam (Cambridge, United Kingdom) and agarose-conjugated
4G10 from Upstate Biotechnology (Charlottesville, VA).
Enzyme-kinase assay
ATIC enzyme and NPM-ALK kinase were immunoprecipitated from 2 mg
of HEK-293T and HEK-293T NPM-ALK total cell lysate, respectively. The
immunoprecipitated proteins were resuspended in kinase buffer (25 mM
Tris-HCl, pH 7.5, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 mM
MgCl2, 5 mM b-glycerophosphate) and then combined at an equal ratio.
The reaction was started by adding 0.2 mM adenosine triphosphate (ATP)
to the mixture and incubating for 30 minutes at 37°C and then stopped by
freezing the samples at80°C.
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Where indicated, CEP14083 (300 nM) was added to the reaction
mixture before adding ATP, then incubated for 30 minutes at 37°C.
Methotrexate (MTX) was added at the indicated concentrations, and the
reaction mixture was incubated again at 37°C for 2 hours.
Measurement of AICAR-FT/IMP-CHase activity
The synthesis of N10-formyl-tetrahydrofolate from (6R, 6S)-5-formyltetrahydrop-
teroil-L-glutamate was performed according to Uyeda and Rabinowitz.27 The
amount of N10-formyl-tetrahydrofolate was assessed by measuring the absor-
bance at 298 nm ( 9.54 cm1M1). AICAR-FT activity was evaluated by
coupling it with the reactions of serine-hydroxy-methyltransferase and methylene-
tetrahydrofolate reductase28: 50g of total cellular lysates or immunoprecipi-
tated proteins was resuspended in the following 1-mL reaction mix: 66 mM Tris
(pH 7.4), 20 mM K3PO4, 5 mM DTT, 2 mM N10-formyl-tetrahydrofolate, 1 mM
AICAR. After 5 minutes, samples were incubated at 37°C in the presence of
1 mM L-serine, 0.2g serine-hydroxy-methyltransferase, and 0.2g of methyl-
ene-tetrahydrofolate reductase. Then (after 2 minutes), 0.05 mM nicotinamide
adenine dinucleotide phosphate was added and the absorbance at 340 nm was
measured for 10 minutes using a Lambda 3 spectrophotometer (PerkinElmer Life
and Analytical Sciences, Waltham, MA). Preliminary experiments showed that,
in these experimental conditions, the oxidation rate of nicotinamide adenine
dinucleotide phosphate was linear throughout the observation time and stoichio-
metrically equivalent to the rate of AICAR disappearance by AICAR-FT (data
not shown). Results were expressed as nmol NADP/minute per mg cell
proteins.
The activities of IMP-CHase or AICAR-FT plus IMP-CHase were
measured by a coupling assay with inosine 5-monophosphate dehydroge-
nase29; 50 g of total cellular lysates or immunoprecipitated proteins were
incubated 30 minutes at 37°C in a reaction mix containing 66 mM Tris
(pH 7.4), 5 mM DTT, 50 mM KCl (final volume, 1 mL). To detect the
activity of IMP-Chase, 0.1 mM N-formylaminoimidazole-4-carboxamide
ribonucleotide (F-AICAR), synthesized as previously described30 and
quantified by measuring the absorbance at 268 nm (  10 900 cm1M1),
was added. For the total activity of AICAR-FT plus IMP-CHase, samples
were incubated with 2 mM N10-formyl-tetrahydrofolate and 1 mM AICAR
instead of F-AICAR. Then 0.1g inosine 5-monophosphate dehydrogenase and
0.1 mM NAD were added. The reduction rate of NAD, stoichiometrically
equivalent to the rate of IMP synthesis under these experimental conditions (data
not shown), was evaluated by measuring the absorbance at 340 nm. The reaction
was linear throughout a 10-minute observation time and the results were
expressed as nmol NADH/min/mg cell proteins.
Measurement of 6-phosphate dehydrogenase,
6-phosphogluconate dehydrogenase, lactic dehydrogenase,
and ornithine decarboxilase activities
Enzymatic activity for glucose 6-phosphate dehydrogenase (G6PD), 6-
phosphogluconate dehydrogenase (6PGD), and lactic dehydrogenase
(LDH) was measured as previously described.31 Ornithine decarboxilase
activity was determined as the amount of 14CO2 released from 0.5 Ci
DL-[1-14C]ornithine, as described.32
Figure 1. LC-MS/MS profiling of NPM-ALK cells identifies a common set of Tyr-phosphorylated proteins. (A) Comparison of the datasets derived from the immunoaffinity
(PhosphoScan) and conventional LC-MS/MS-based proteomic approaches (Table 1). (B) Immunoaffinity profiling of NPM-ALK ALCL cell lines compared with NPM-ALK-positive
HEK-293T-Rex cells. (C) Comparative PhosphoScan performed on 6 differentALCL cell lines. (D) Tyrosine phosphorylated sites on the NPM-ALK protein are represented with a gray dot
(9 of these were identified in all ALK cell lines); the star represents newly discovered sites. Tyrosine sites known to interact with IRS1, SHC, and PLC-g are indicated. (E) The
phosphorylation status of selected proteins was assessed inALCL cell lines after treatment with CEP14083 and detected by phospho-specific antibodies as indicated.
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Results
LC-MS/MS identifies a set of phosphotyrosine peptides in
NPM-ALK cells
To determine a global profile of tyrosine (Tyr)–phosphorylated
proteins in NPM-ALK cells, we used 2 different LC-MS/MS-based
proteomic approaches. Both methods implied immunoaffinity
precipitation of Tyr-phosphorylated proteins by specific anti–
phosphotyrosine antibodies, but whereas the first approach re-
quired the excision of bands of interest from sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (15-20 bands differen-
tially expressed, compared with control), the second approach
allowed a more global mapping of Tyr-phosphorylated peptides.
We have first assessed the feasibility of both strategies using a
tetracycline-inducible NPM-ALK HEK-293T-Rex cell line (Figure
1A). A list of 40 common proteins detected by both approaches is
provided in Table 1. These studies confirmed several known
interactors of NPM-ALK (STAT3, SHC, and PTPN11)21,26,33 and
discovered novel Tyr-phosphorylated proteins. The immunoaffinity
profiling of phosphopeptides (PhosphoScan)15 identified a total of
167 peptides (corresponding to 137 phosphorylated proteins), grant-
ing a better specificity compared with conventional approaches
(Table S1). This technique excludes all proteins that are not
phosphorylated but bind specifically to a phosphorylated peptide
and identifies multiple Tyr-phosphorylated peptides corresponding
to the same protein, providing a higher degree of confidence.
Given that the HEK-293T–inducible system uses a highly
controlled but ectopic NPM-ALK expression in a nonlymphoid
cells, we applied the PhosphoScan technology (Cell Signaling
Table 1. Proteins identified in HEK 293T NPM-ALK cells by 2 complementary proteomic approaches
Gene
symbol
NCBI
access no. Protein
No. of
peptides*
Sequence
coverage,* %
Kinases and phosphatases
ALK NP_004295 Anaplastic lymphoma kinase Ki-1 30 38
GSK3A NP_063937 Glycogen synthase kinase 3  1 2
PFKP NP_002618 Phosphofructokinase, platelet 3 3
PKM2 NP_872270 Pyruvate kinase 3 isoform 2 8 20
PTPN11 NP_002825 Shp2 4 6
Metabolism
ACLY NP_001087 ATP citrate lyase 6 6
CUL2 NP_003582 Cullin 2 5 9
DDX3X NP_004651 DEAD/H box-3 5 7
DNAJC7 NP_003306 DnaJ (Hsp40) homolog 7 13
ENO1 NP_001419 Enolase 1 48 57
HNRPA1 NP_112420 Heterogeneous nuclear ribonucleoprotein A1 5 22
HNRPA2B1 NP_112533 Heterogeneous nuclear ribonucleoprotein A2/B1 11 30
HNRPF NP_004957 Heterogeneous nuclear ribonucleoprotein F 3 8
HNRPH1 NP_005511 Heterogeneous nuclear ribonucleoprotein H1 2 3
HNRPR NP_005817 Heterogeneous nuclear ribonucleoprotein R 2 3
HNRPU NP_004492 Heterogeneous nuclear ribonucleoprotein U 11 12
SFPQ NP_005057 Splicing factor proline/glutamine rich 5 5
TARS NP_689508 Threonyl-tRNA synthetase 3 4
ZNF598 NP_835461 Zinc finger protein 598
Adaptor proteins
HGS NP_004703 Hepatocyte growth factor-regulated tyrosine kinase substrate 3 4
HSP90AB1 NP_031381 Heat shock 90-kDa protein 1, 	 25 25
HSPA1B NP_005337 Heat shock 70-kDa protein 1B 16 28
HSPA2 NP_068814 Heat shock 70-kDa protein 2 1 1
HSPA4 NP_002145 Heat shock 70-kDa protein 4 1 1
HSPA8 NP_006588 Heat shock 70-kDa protein 8 1 3
IRS4 NP_003595 Insulin receptor substrate 4 48 27
RPLP0 NP_444505 Ribosomal protein P0 3 10
SHC NP_003020 SHC 2 2
TRAP1 NP_057376 Tumor necrosis factor type 1 receptor-associated protein 1 2
Signal transduction
ARHGEF2 NP_004714 rho/rac guanine nucleotide exchange factor 2 1 1
CNOT1 NP_057368 KIAA1007 protein; CCR4-NOT transcription complex, subunit 1 1 1
LMO7 NP_005349 LIM domain only 7 1 1
STAT3 NP_644805 Signal transducer and activator of transcription 3 2 2
YWHAG NP_036611 14-3–3 
 7 24
Cytoskeleton
ACTB NP_001092 	 actin 8 20
BICD2 NP_056065 Bicaudal D homolog 2 7 11
VIM NP_003371 Vimentin 18 38
Unknown function
FHL1 NP_001440 Four and a half LIM domains 1 2 6
NCAPH NP_056156 Barren 7 13
UBAP2L NP_055662 NICE-4 protein 4 6
*Number of peptides and sequence coverage refer to IA enrichment method only.
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Table 2. Tyrosine phosphorylated peptides identified by PhosphoScan in 6 ALK ALCL cell lines (cutoff level, 67%) versus the ALK cell
line Mac-1
Gene
symbol
pTyr
site Peptide Karpas299 SU-DHL1 JB-6 TS SR-786 SUP-M2 Mac-1
Kinases
ALK 1078* HQELQAMQMELQSPEyK ● ● ● ● ● ●
ALK 1092* TSTIMTDyNPNYCFAGK ● ● ● ● ● ●
ALK 1096* TSTIMTDYNPNyCFAGK ● ● ● ● ● ●
ALK 1131* GLGHGAFGEVyEGQVSGMPNDPSPLQVAVK ● ● ● ●
ALK 1278* DIyRASYYR ● ● ● ● ● ●
ALK 1282* DIyRASyYR ● ● ● ● ● ●
ALK 1283* DIyRASyyR ● ● ● ● ● ●
ALK 1507* NKPTSLWNPTyGSWFTEKPTK ● ● ● ● ● ●
ALK 1584* HFPCGNVNyGYQQQGLPLEAATAPGAGHyEDTILK ● ● ● ●
ALK 1586* HFPCGNVNYGyQQQGLPLEAATAPGAGHyEDTILK ● ● ● ● ● ●
ALK 1604* HFPCGNVNYGyQQQGLPLEAATAPGAGHyEDTILK ● ● ● ● ● ●
CDC2 15 IEKIGEGTyGVVYK ● ● ● ● ● ●
CDK3 15 VEKIGEGTyGVVYK ● ● ● ● ● ● ●
DYRK1A 321 IYQyIQSR ● ● ● ● ● ● ●
GSK3B 279 GEPNVSyICSR ● ● ● ● ● ● ●
HIPK1 352 AVCSTyLQSR ● ● ● ● ● ●
MAPK1 187 VADPDHDHTGFLTEyVATR ● ● ● ● ● ●
PGK1 195 ELNyFAK, KELNyFAK ● ● ● ● ●
PIP5K2B 93 FKEyCPMVFR ● ● ● ●
PRPF4B 849 LCDFGSASHVADNDITPyLVSR ● ● ● ● ● ● ●
Metabolism
ACLY 682 TTDGVyEGVAIGGDRYPGSTFMDHVLR ● ● ● ● ● ●
ATIC 104 VVACNLyPFVK ● ● ● ● ● ●
DCP1B 110 LSIyGIWFYDKEECQR ● ● ● ●
EIF3S7 318 NLAMEATyINHNFSQQCLR ● ● ● ●
EIF3S9 525 NGDyLCVK ● ● ● ● ●
ELP3 202 NLHDALSGHTSNNIyEAVK ● ● ● ● ●
ENO1 43 AAVPSGASTGIyEALELR ● ● ● ● ● ● ●
ENO1 286 SFIKDyPVVSIEDPFDQDDWGAWQK ● ● ● ●
HIST1H4I 51 ISGLIyEETR ● ● ● ●
HNRPF 306 ATENDIyNFFSPLNPVR ● ● ● ●
HSPCB 483 SIyYITGESKEQVANSAFVER ● ● ● ● ● ●
LDHA 238 QVVESAyEVIK ● ● ● ● ● ● ●
LDHB 239 MVVESAyEVIK ● ● ● ● ● ● ●
MDH2 56 LTLyDIAHTPGVAADLSHIETK ● ● ● ●
NIT2 145 TLSPGDSFSTFDTPyCR ● ● ● ● ● ●
NYREN18 126 SKIAETFGLQENyIK ● ● ● ●
PABPC1 54 SLGyAYVNFQQPADAER ● ● ● ● ● ●
PBEF1 188 YLLETSGNLDGLEyKLHDFGYR ● ● ● ● ●
PKM2 104 TATESFASDPILyRPVAVALDTKGPEIR ● ● ● ● ● ● ●
PRIM2A 381 IILSNPPSQGDyHGCPFR ● ● ● ● ●
PSMA2 23 LVQIEyALAAVAGGAPSVGIK ● ● ● ● ●
PSMA2 97 KLAQQYyLVYQEPIPTAQLVQR ● ● ● ● ●
PSMB4 102 VNNSTMLGASGDyADFQYLK ● ● ● ● ●
RNPS1 205 GyAYVEFENPDEAEK ● ● ● ●
RPL18A 63 SSGEIVyCGQVFEK ● ● ● ● ● ●
RPL31 103 NEDEDSPNKLyTLVTYVPVTTFK ● ● ● ● ● ●
RPL7 139 IVEPyIAWGYPNLK ● ● ● ● ●
RPLP0 24 IIQLLDDyPKCFIVGADNVGSK ● ● ● ● ● ● ●
RPS13 37 LTSDDVKEQIyK ● ● ● ●
TXNRD1 11 SyDYDLIIIGGGSGGLAAAK ● ● ● ●
TXNRD1 13 SYDyDLIIIGGGSGGLAAAK ● ● ● ● ● ●
WDR54 33 NLTyFGVVHGPSAQLLSAAPEGVPLAQR ● ● ● ●
G-proteins
GDI2 203 TDDYLDQPCyETINR ● ● ● ● ●
RASA1 615 HFTNPyCNIYLNSVQVAK ● ● ● ● ● ●
Adaptor proteins
GRLF1 1105 NEEENIySVPHDSTQGK ● ● ●
HSPA4 336 LKKEDIyAVEIVGGATR ● ● ● ● ●
HSPD1 227 GYISPyFINTSK ● ● ● ●
*The indicated ALK pTyr sites refer to the full lenght ALK receptor, and they correspond to NPM-ALK pTyr sites 138, 152, 156, 191, 338, 342, 343, 567, 644, 646, and 664,
respectively
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Technology) to a panel of NPM-ALK–positive ALCL lines, a
model that better reproduces the ALK lymphoproliferative pro-
cesses. This analysis revealed a total of 372 Tyr-phosphorylated
peptides within 290 proteins (Figure 1B), which included approxi-
mately half of the peptides previously identified in NPM-ALK
HEK-293T cells. A further analysis, performed to find the proteins
shared by all cell lines and applying both techniques (data not
shown), led to the discovery of a small cluster of 26 Tyr-
phosphorylated proteins (Table S2), which were also largely
represented in previous analyses. We then compared the data
obtained from the phospho-tyrosine immunoprecipitation of 6
ALK ALCL lines and found a panel of 372 peptides (within
290 different proteins), 31 of which were shared by all 6 ALCL cell
lines (Figure 1C).
Of these 31 Tyr-phosphorylated peptides, 12 were also shared
by the ALK control T cell lymphoblastoid line Mac-1 (CD30/
STAT3/STAT5-positive). These phosphopeptides belonged to pro-
teins with kinase activity (GSK3B (Y279), CDK3 (Y15), DYRK1A
(Y321), PRPF4B (Y849]) or metabolic enzymes (ENO-1 [Y43],
LDH-A [Y238], LDH-B [Y239], PKM [Y104]) frequently found in
proliferating cells. Notably, some well-documented ALK interac-
tors, such as SHC-1 (Y427) and STAT3 (iso1 Y704, and iso2
Y705), were also found. Similar findings were obtained by
comparison of ALK cell lines to other 2 ALK lymphoid cell
lines (CCRF-CEM and Jurkat, data not shown).
Nineteen peptides were exclusively found in ALK cells, and
9 belonged to the ALK protein itself. Noteworthy, 4 of these were
novel ALK phosphorylation sites (Figure 1D). The remaining
10 peptides identified proteins linked to cell metabolism, including
ATIC (Y104) and ATP-citrate lyase (ACLY, Y682), G-proteins
(GTPase-activating protein RasA1, Y615), and ribosomal proteins
(RPs) L31 (Y103) and L18a (Y63). Using a lower cutoff level
(peptides identified in  4 of 6 cell lines), we could define a larger
protein set with several novel entities (Table 2); among them,
ribosomal (L7 [Y139], S13 [Y37], and P0 [Y24]) and structural
proteins, including VASP (Y38), a cytoskeletal-regulating protein
recently identified as part of BCR-ABL phospho-tyrosine
signature.17
ALK inhibition defines a common phospho-tyrosine signature
To identify phosphorylated proteins playing a pathogenic role in
NPM-ALK-mediated transformation, we analyzed the Tyr-
phosphorylation signature of ALK ALCL lines after abrogating
the expression or the activity of NPM-ALK by RNA interfer-
ence (RNAi)11 or by a small molecule ALK inhibitor,23 respec-
tively. Using an inducible shRNA and quantitative proteomic
approach, we demonstrated that a total of 101 peptides were no
longer phosphorylated after ALK silencing, whereas 24 became
phosphorylated and 35 were apparently unaffected by ALK
RNAi (Table S3).
To exclude off-target effects by RNAi, ALCL cells were treated
with a small-molecule ALK inhibitor (CEP14083) or by a control
compound (CEP11988).23 These studies revealed a total of 138 phos-
phopeptides lost after ALK inhibition, whereas 109 new peptides
became phosphorylated and 226 were unchanged after ALK
inhibition (Table S4), with a good overlap between the RNAi and
ALK inhibitor datasets. Nevertheless, small or no variations of
well-known ALK-related Tyr-phosphorylated proteins were seen
by the single approach or the combined methods (ie, STAT3). Thus,
we used a Stable Isotope Labeling of Amino acid in Cell culture
approach on TS cells after induction of a specific ALK shRNA. The
PhosphoScan technology allowed the identification of variations in
the phosphorylation levels of many proteins, including known
NPM-ALK downstream targets and novel proteins, undetectable
using previous analyses (Table 3). For instance, a significant
down-modulation of p-STAT3 signal (13-fold inhibition) was
observed after ALK silencing. Moreover, Western blot validation
confirmed the abrogation of NPM-ALK–dependent phosphoryla-
tion of several downstream targets (Figure 1E). A combined
approach may identify a common set of tyrosine-phosphorylated
proteins whose status correlates more precisely to ALK activity.
NPM-ALK induces ATIC and VASP phosphorylation
To validate new ALK interactors, we selected 2 biologically
relevant proteins: ATIC and VASP. ATIC is an enzyme involved in
purine biosynthesis and VASP is a protein regulating actin polymer-
ization and cytoskeletal reorganization.3,34 The MS/MS spectra of
both phosphopeptides displayed an Xcorr value larger than 2.3 and
a well-represented proline peak, suggesting a correct assignment35
(Figure 2A,B). Phosphorylated ATIC and VASP were confirmed by
immunoprecipitation and Western blot in all NPM-ALK–positive
lines. Notably, ATIC Tyr-phosphorylation was also detectable in
control lines (CEM and Jurkat), suggesting that ATIC might be a
Table 2. Tyrosine phosphorylated peptides identified by PhosphoScan in 6 ALK ALCL cell lines (cutoff level, 67%) versus the ALK cell
line Mac-1 (continued)
Gene
symbol
pTyr
site Peptide Karpas299 SU-DHL1 JB-6 TS SR-786 SUP-M2 Mac-1
IRS1 46 AASEAGGPARLEyYENEKK ● ● ●
SHC1 427 ELFDDPSyVNVQNLDK ● ● ● ● ● ● ●
TRAP1 498 NIyYLCAPNR ● ● ● ● ● ●
Transcription factors
EEF1A1 141 EHALLAyTLGVK ● ● ● ● ● ●
STAT3 704 YCRPESQEHPEADPGAAPyLK ● ● ● ● ● ● ●
STAT3 705 YCRPESQEHPEADPGSAAPyLK ● ● ● ● ● ● ●
Cytoskeleton
ACTB 218 DIKEKLCyVALDFEQEMATAASSSSLEK ● ● ● ●
DNCH1 3379 NYMSNPSYNyEIVNR ● ● ● ● ●
STOML2 124 ASYGVEDPEyAVTQLAQTTMR ● ● ● ●
VASP 38 VQIyHNPTANSFR ● ● ● ● ●
VIM 116 TNEKVELQELNDRFANyIDKVR, FANyIDKVR ● ● ● ●
WDR1 238 AHDGGIyAISWSPDSTHLLSASGDKTSK ● ● ● ● ●
*The indicated ALK pTyr sites refer to the full-length ALK receptor, and they correspond to NPM-ALK pTyr sites 138, 152, 156, 191, 338, 342, 343, 567, 644, 646, and 664,
respectively
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substrate of other kinases (Figure 2C). In a subsequent survey of
243 cell lines, we found that p-ATIC (Tyr 104) was detectable in all
ALK ALCL, and in 1 of 3 non–small cell lung cancer lines
carrying p-ALK. Among ALK nonlymphoid samples, p-ATIC
was documented in 5 of 237 lines expressing activated kinases
(ABL, EGFR, and PDGFR) and 7 of 148 tumor samples, some of
which displayed detectable p-Met.18,36
To assess whether Tyr-phosphorylation of ATIC and VASP was
regulated by the NPM-ALK, both proteins were immunoprecipi-
tated and analyzed by Western blotting. Figure 3A shows that the
down-regulation of NPM-ALK in ALCL cell lines by RNAi
coincided with a significant decrease of p-ATIC and p-VASP,
whereas their expression remained unaffected. Similarly, treatment
of cells with the ALK inhibitor, CEP14083, but not the control
CEP11988, led to a significant decrease of p-ATIC and p-VASP
(Figure 3B).
Having determined that ATIC and VASP phosphorylation is
mediated by ALK, we subsequently investigated their physical
association with NPM-ALK. ATIC and VASP coprecipitated with
NPM-ALK, and this interaction was largely lost when the expres-
sion of NPM-ALK was down-regulated via ALK RNAi (Figure
3C) or, alternatively, when its kinase activity was pharmacologi-
cally repressed (Figure 3D).
NPM-ALK enhances ATIC enzymatic activity
To test whether the Tyr-phosphorylation of ATIC modulates its
enzymatic activity, we set 3 different assays, determining the
transformylase (AICAR-FT), cyclohydrolase (IMP-CHase), and
the total ATIC activity. NPM-ALK was enriched by immunopre-
cipitation using NPM-ALK HEK-293T-Rex cells and then
combined in vitro with wild-type-ATIC from HEK-293T. Figure
4A shows that ATIC activity was enhanced in the presence of
NPM-ALK, whereas it remained at the basal level when
NPM-ALK was inhibited or when an inactive NPM-ALK
(NPM-ALKK210R) was used. The finding that ATIC activity was
enhanced by its phosphorylation was further demonstrated using
lambda-phosphatase capable to dephosphorylate p-ALK species
(Figure 4B).
To exclude that the increased activity of ATIC could be the
result of the neoplastic phenotype, we measured in parallel the
activity of other metabolic enzymes (LDH, G6PD, 6PGD, and
ODC). LDH was selected as a control because it was highly
phosphorylated in NPM-ALK-positive cells (according to LC-
MS/MS data), although it was not modulated by NPM-ALK kinase
activity (Figure 5A). Considering that ATIC can be a ALK partner
with ATIC-ALK fusion chimera,9 we stably transfected an ATIC-
ALK construct into the HEK-293T-Rex cells and showed that the
Figure 2. Tyrosine phosphopeptides are identified in ALK ALCL cells. (A) MS/MS spectrum of tyrosine-phosphorylated peptide VVACNLYPFVK, assigned to the protein
ATIC (percentage coverage, 1.8% of total sequence). (B) MS/MS spectrum of tyrosine-phosphorylated peptide VQIYHNPTANSFR, assigned to the protein VASP (percentage
coverage, 3.4% of total sequence). (C) Total protein expressions (top panel) and phosphorylation status (bottom panel) as assayed by Western blot with the indicated
antibodies.
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wild-type ATIC activity was also enhanced by this fusion, similar
to the NPM-ALK chimera (Figure 5B).
Next, to test whether the up-regulation of ATIC activity
could be associated with a neoplastic phenotype and/or with
other kinases, we transfected the HEK-293T cells with TPR-
Met, c-Myc, and Ras expressing constructs. Figure 5C shows
that all fusion kinases increased the ATIC activity, but this effect
was significantly higher in NPM-ALK and in Ras (RasV12)
transfected cells. Because Ras is a downstream target of
NPM-ALK,37 we tested whether it was required in the NPM-
ALK–mediated ATIC activation. Figure 5D shows that NPM-
ALK–driven activation of ATIC was not affected by a dominant
negative Ras construct.
To confirm our findings in a model that mimics human ALCL,
we treated ALK (SU-DHL1, TS, and JB-6) and ALK (Mac-1)
ALCL cell lines with CEP14083, and then we evaluated the activity
of ATIC and other metabolic enzymes (G6PD and ODC). All
enzymatic measurements were performed shortly after the pharma-
cologic inhibition and in viable cells, as determined by tetramethyl-
rhodamine methyl ester (TMRM) staining. ATIC activity was
gradually reduced over a 6-hour time course after CEP14083
treatment in ALK cells, whereas no effect was documented in
Figure 3. ATIC and VASP phosphorylation is depen-
dent on NPM-ALK kinase activity. (A) Phospho-
tyrosine containing proteins were first immunoprecipi-
tated (IP) with a specific anti (pTyr) antibody and
subsequently blotted with the indicated antibodies.
(B) Lysates from ALK ALCL cell lines (TS and SU-
DHL1), treated with small-molecule ALK inhibitor
(CEP14083) or a control compound (CEP11988), were
immunoprecipitated and blotted with the indicated anti-
bodies. (C) Total lysates from doxycycline-treated TS
TTAA5 cells (1 mg/mL for 84 and 96 hours) were IP with
a specific anti-ATIC or anti-VASP antibody and blotted
with anti-ALK antibody. (D) Total proteins from TS cells
(300 nM of CEP14083 or CEP11988) were IP with a
specific anti-ATIC or anti-VASP antibody and blotted
with anti-ALK antibody.
Figure 4. ATIC activity is enhanced in the presence
of NPM-ALK in vitro. (A) Immunoprecipitated ATIC
was combined with the active NPM-ALK kinase (iso-
lated from wild-type HEK-293T cells and NPM-ALK
HEK-293T cells, respectively) or with a mutated NPM-
ALKK210R kinase (from NPM-ALKK210R–positive HEK-
293T cells), with and without theALK inhibitor CEP14083
(6 hours). Total or specific ATIC activity was measured
as described in “Measurement of AICAR-FT/IMP-
CHase activity.” (B) ATIC enzymatic activities were also
determined in the presence of lambda phosphatase
(1 mg for 1 hour). *P  .001.
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ALK cells (Figure 6). Notably, both G6PD and ODC activities
remained unaffected under these conditions.
NPM-ALK protects cancer cells from the effects of MTX
To test whether the enzymatic modulation of ALK-mediated
ATIC activity could be biologically relevant, we studied ATIC
inhibition via MTX, a folic acid analog.38,39 MTX decreased the
ATIC transformylase and the total enzyme activity, whereas its
cyclohydrolase function remained unaffected (Figure 7A). In
the presence of NPM-ALK, the effect of the MTX was partially
abrogated, and higher doses of MTX were required to produce
similar inhibitory rates compared with samples lacking NPM-
ALK. To demonstrate that the NPM-ALK activity was neces-
sary, we inhibited ALK kinase activity by CEP14083, and this
led to a reduced ATIC transformylase activity in the presence of
MTX (Figure 7B). Finally, to validate these findings in a
cell-based assay, NPM-ALK or NPM-ALKK210R retroviral par-
ticles were transduced into T-cell lymphoma cells (CEM). Cells
were then treated with the MTX and ATIC activity was
determined. ATIC was impaired by MTX, whereas other cellular
enzymes (LDH, G6PD, and 6PGD) were not affected (data not
shown), either in control or NPM-ALKK210R cells. On the
contrary, the inhibition of ATIC by MTX was less pronounced in
ALK CEM cells (Figure 7C).
Discussion
We used 2 proteomic methods, together with a functional valida-
tion approach, to identify novel molecules downstream to NPM-
ALK. Performing global HTP posttranscriptional analyses offers a
new and powerful approach to dissect pathogenic mechanisms and
to apply novel technologies for the diagnosis of malignancy,
identification of biomarkers, discovery of targets, and design of
tailored therapies.2-4,40
We confirmed that ALK signaling is associated with a well-
defined transcriptional signature13,14 and that ALK cells preferen-
tially express phosphorylated proteins with specific functions.10
Our data revealed some proteins in common with those reported in
previous HTP proteomic studies and identified new targets.16,41-43
Relevant proteins were either known mediators of the ALK-
signaling or novel proteins, including transcription factors, cytoskel-
etal/structural, motor/adhesion, and ribosomal proteins or proteins
involved in the nucleic acid and/or protein metabolism.
Figure 5. The ATIC activity is enhanced by NPM-ALK in HEK-293T-Rex cells. (A) NPM-ALK inducible HEK-293T-Rex cells were induced with tetracycline with and
without CEP14083 ALK inhibitor. p-NPM-ALK was determined by Western blotting using anti–p-ALK antibodies. ATIC and LDH enzymatic activities were evaluated;
*P  .001. (B) HEK-293T-Rex cells containing an inducible ATIC-ALK construct were induced with tetracycline and/or with CEP14083. Western blotting analysis
confirmed ALK expression and phosphorylation. Enzymatic activity of ATIC and LDH was evaluated. (C) Cell lysates of transiently transfected HEK-293T cells
(NPM-ALK, NPM-ALKK210R, ATIC-ALK, TPR-Met, c-myc, and the self-activating form of Ras, Ras V12) were tested for their ATIC and LDH enzymatic activity. *P  .001,
**P  .05. (D) Cell lysates from transiently transfected HEK-293T cells with NPM-ALK, NPM-ALKK210R, and/or a Ras DN, respectively, were tested for their ATIC and
LDH enzymatic activity.
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Proteomic studies are successful tools for the diagnosis of ALCL42
and for the identification of ALK-related proteins and/or adaptor
molecules.26,44 Our findings are in line with those of Rush et al, who
have first demonstrated that HTP proteomics of Tyr-phosphorylated
peptides provide selective signatures, identifying key regulators and
predicting signaling pathways.15 Although proteomic studies have
unveiled new players within kinase-driven signaling, it is well estab-
lished that any molecular signature is not fully representative of the
tumorigenic events leading to cellular transformation. Indeed, each
genetic alteration may be simply associated with a given neoplastic
phenotype but may lack any pathogenetic role; these lesions are now
referred to as “passengers.” Although these defects do not maintain the
neoplastic phenotype, they often represent “tumor-associated biomark-
ers” capable of better stratifying tumors or patients allowing better
patient follow-up during treatment. Pathogenetically relevant lesions,
referred to as “drivers,” have a more pertinent impact and represent ideal
targets for novel therapies. Thus, it has become imperative to design
strategies dissecting “passengers” from “drivers.”
Although proteomic approaches may be more informative than
genomic analyses, functional validation studies are required to
dissect the relationships between causal events and phenotypes and
to define the tumorigenic contribution of each change.
Because HTP analyses are often descriptive, we adopted 2 alterna-
tive strategies to gain more insights into ALK-mediated transformation.
First, we have compared the phospho-profile obtained from ALK
ALCL cell lines with those derived from cells ectopically expressing
ALK fusions, in the presence or in the absence of ALK signaling. These
models have revealed a restricted set of phosphoproteins shared byALK
cells, in different cellular contexts. Although this may be restrictive and
could result in the loss of relevant ALK-associated targets, it defines a
limited number of proteins, whose phosphorylation status is highly
reproducible and strictly dependent on ALK signaling. Second, to
identify a biologically relevant set of ALK-associated proteins, we used
an ALK inhibitor and performed a quantitative determination of
phosphorylation changes. These studies have shown that determining
the level of protein phosphorylation is necessary to identify appropriate
targets, many of them undetectable using semiquantitative approaches.
To validate newly defined ALK-associated proteins, we performed
biochemical studies, which confirmed that VASP and ATIC were
associated with NPM-ALK and phosphorylated. More importantly, we
demonstrated that ATIC phosphorylation enhanced its enzymatic activ-
ity. This is the first demonstration that ALK-mediated phosphorylation
leads to an enhanced metabolic activity of a substrate, which may
contribute to cell transformation. Enhanced purine synthesis sustains
cell proliferation, and its therapeutic inhibition has been adopted to
hamper tumor growth in many human malignancies. The discovery that
ALK posttranscriptional modifications may change the activity of a key
enzyme is important because this observation may be applied to other
kinase-driven tumors. This hypothesis is supported by the detection of
p-ATIC in many tumor cell lines and fresh samples.18,36 Thus, it is
tempting to speculate that the detection of p-ATIC may be useful to
predict the response to antifolate agents and facilitate the design of more
efficacious therapeutic protocols. The identification of tumorigenic
molecules has served as a platform to improve chemotherapeutic
protocols using conventional cancer agents and to open a new era in
anticancer research in which new targeted compounds are being
developed to supplant the more toxic traditional anticancer drugs.
Figure 6. The inhibition of NPM-ALK abrogated the ATIC activity in ALCL cells. The enzymatic activity of ATIC, G6PD, and ODC was measured in ALK (TS, SU-DHL1,
JB-6) and ALK (Mac-1) lymphoblastoid cell lines after treatment with a specific ALK inhibitor, as described in “Measurement of AICAR-FT/IMP-CHase activity.”
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Here we provided new evidence on a posttranscriptional
modification of a key purine synthesis enzyme, which may predict
response to antifolate analogs. Detailed knowledge of ATIC
enzyme activity in human tumors may allow the identification of
low responders and thus the application of ad hoc therapeutic
strategies or patient-related dose regimens.
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